Avacare has invested in various R&D projects and companies. In 2017, we acquired biotech firm, Afrigen Biologics, to supply a steady pipeline of cutting-edge proprietary products.
Afrigen is the only adjuvant and nanotech formulation laboratory on the continent. This unique biotech start-up boasts seven PhDs, four MScs and two engineers dedicated to next-generation adjuvants for increased safety and efficacy of human and animal vaccines. A first for Africa, the Afrigen platform recently launched Nanosomal CBD+, a superior bioavailable CBD.